Cargando…

Severe strongyloidiasis: a systematic review of case reports

BACKGROUND: Strongyloidiasis is commonly a clinically unapparent, chronic infection, but immuno suppressed subjects can develop fatal disease. We carried out a review of literature on hyperinfection syndrome (HS) and disseminated strongyloidiasis (DS), in order to describe the most challenging aspec...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonfrate, Dora, Requena-Mendez, Ana, Angheben, Andrea, Muñoz, Jose, Gobbi, Federico, Van Den Ende, Jef, Bisoffi, Zeno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598958/
https://www.ncbi.nlm.nih.gov/pubmed/23394259
http://dx.doi.org/10.1186/1471-2334-13-78
_version_ 1782262859067031552
author Buonfrate, Dora
Requena-Mendez, Ana
Angheben, Andrea
Muñoz, Jose
Gobbi, Federico
Van Den Ende, Jef
Bisoffi, Zeno
author_facet Buonfrate, Dora
Requena-Mendez, Ana
Angheben, Andrea
Muñoz, Jose
Gobbi, Federico
Van Den Ende, Jef
Bisoffi, Zeno
author_sort Buonfrate, Dora
collection PubMed
description BACKGROUND: Strongyloidiasis is commonly a clinically unapparent, chronic infection, but immuno suppressed subjects can develop fatal disease. We carried out a review of literature on hyperinfection syndrome (HS) and disseminated strongyloidiasis (DS), in order to describe the most challenging aspects of severe strongyloidiasis. METHODS: We conducted a structured search using PubMed to collect case reports and short case series on HS/DS published from 1991 to 2011. We restricted search to papers in English, Spanish, Italian and French. Case reports were classified as HS/DS according to given definitions. RESULTS: Records screened were 821, and 311 were excluded through titles and abstract evaluation. Of 510 full-text articles assessed for eligibility, 213 were included in qualitative analysis. As some of them were short case series, eventually the number of cases analyzed was 244. Steroids represented the main trigger predisposing to HS and DS (67% cases): they were mostly administered to treat underlying conditions (e.g. lymphomas, rheumatic diseases). However, sometimes steroids were empirically prescribed to treat signs and symptoms caused by unsuspected/unrecognized strongyloidiasis. Diagnosis was obtained by microscopy examination in 100% cases, while serology was done in a few cases (6.5%). Only in 3/29 cases of solid organ/bone marrow transplantation there is mention of pre-transplant serological screening. Therapeutic regimens were different in terms of drugs selection and combination, administration route and duration. Similar fatality rate was observed between patients with DS (68.5%) and HS (60%). CONCLUSIONS: Proper screening (which must include serology) is mandatory in high - risk patients, for instance candidates to immunosuppressive medications, currently or previously living in endemic countries. In some cases, presumptive treatment might be justified. Ivermectin is the gold standard for treatment, although the optimal dosage is not clearly defined in case of HS/DS.
format Online
Article
Text
id pubmed-3598958
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35989582013-03-17 Severe strongyloidiasis: a systematic review of case reports Buonfrate, Dora Requena-Mendez, Ana Angheben, Andrea Muñoz, Jose Gobbi, Federico Van Den Ende, Jef Bisoffi, Zeno BMC Infect Dis Research Article BACKGROUND: Strongyloidiasis is commonly a clinically unapparent, chronic infection, but immuno suppressed subjects can develop fatal disease. We carried out a review of literature on hyperinfection syndrome (HS) and disseminated strongyloidiasis (DS), in order to describe the most challenging aspects of severe strongyloidiasis. METHODS: We conducted a structured search using PubMed to collect case reports and short case series on HS/DS published from 1991 to 2011. We restricted search to papers in English, Spanish, Italian and French. Case reports were classified as HS/DS according to given definitions. RESULTS: Records screened were 821, and 311 were excluded through titles and abstract evaluation. Of 510 full-text articles assessed for eligibility, 213 were included in qualitative analysis. As some of them were short case series, eventually the number of cases analyzed was 244. Steroids represented the main trigger predisposing to HS and DS (67% cases): they were mostly administered to treat underlying conditions (e.g. lymphomas, rheumatic diseases). However, sometimes steroids were empirically prescribed to treat signs and symptoms caused by unsuspected/unrecognized strongyloidiasis. Diagnosis was obtained by microscopy examination in 100% cases, while serology was done in a few cases (6.5%). Only in 3/29 cases of solid organ/bone marrow transplantation there is mention of pre-transplant serological screening. Therapeutic regimens were different in terms of drugs selection and combination, administration route and duration. Similar fatality rate was observed between patients with DS (68.5%) and HS (60%). CONCLUSIONS: Proper screening (which must include serology) is mandatory in high - risk patients, for instance candidates to immunosuppressive medications, currently or previously living in endemic countries. In some cases, presumptive treatment might be justified. Ivermectin is the gold standard for treatment, although the optimal dosage is not clearly defined in case of HS/DS. BioMed Central 2013-02-08 /pmc/articles/PMC3598958/ /pubmed/23394259 http://dx.doi.org/10.1186/1471-2334-13-78 Text en Copyright ©2013 Buonfrate et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Buonfrate, Dora
Requena-Mendez, Ana
Angheben, Andrea
Muñoz, Jose
Gobbi, Federico
Van Den Ende, Jef
Bisoffi, Zeno
Severe strongyloidiasis: a systematic review of case reports
title Severe strongyloidiasis: a systematic review of case reports
title_full Severe strongyloidiasis: a systematic review of case reports
title_fullStr Severe strongyloidiasis: a systematic review of case reports
title_full_unstemmed Severe strongyloidiasis: a systematic review of case reports
title_short Severe strongyloidiasis: a systematic review of case reports
title_sort severe strongyloidiasis: a systematic review of case reports
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598958/
https://www.ncbi.nlm.nih.gov/pubmed/23394259
http://dx.doi.org/10.1186/1471-2334-13-78
work_keys_str_mv AT buonfratedora severestrongyloidiasisasystematicreviewofcasereports
AT requenamendezana severestrongyloidiasisasystematicreviewofcasereports
AT anghebenandrea severestrongyloidiasisasystematicreviewofcasereports
AT munozjose severestrongyloidiasisasystematicreviewofcasereports
AT gobbifederico severestrongyloidiasisasystematicreviewofcasereports
AT vandenendejef severestrongyloidiasisasystematicreviewofcasereports
AT bisoffizeno severestrongyloidiasisasystematicreviewofcasereports